C&CURE & ADVANCEMENTS
Cure & Advancements/November 3, 2026/2 min read

Early Digestive Markers Found in Babies Who Develop Type 1 Diabetes

A new study identified lower levels of pancreatic digestive enzymes in infants who later developed type 1 diabetes or autoimmune markers. Researchers say this finding could help explain how type 1 begins, though it's not ready to be used as a screening test.

Research summaryVideo report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

  • Babies who developed type 1 diabetes had lower levels of fecal elastase 1 (a pancreatic enzyme marker) in their first 6 months of life
  • Blood trypsin levels were also lower 12 to 18 months before a type 1 diagnosis
  • This is an observational finding from 301 at-risk infants followed from birth in the ENDIA study
  • These differences may offer clues about how type 1 diabetes develops, but this is not a test families can use today

What the ENDIA Study Found

Researchers tracking 301 at-risk infants from birth discovered an interesting pattern: babies who later developed type 1 diabetes or early autoimmune markers showed lower levels of digestive enzymes early in life. Specifically, fecal elastase 1—a marker of pancreatic digestive function—was reduced in infants during their first 6 months. Additionally, a blood marker called trypsin was lower 12 to 18 months before a type 1 diagnosis occurred.

The study was published in Diabetes Care and represents part of the larger ENDIA research effort, which aims to understand the origins of type 1 diabetes in infants at genetic risk.

Why This Matters for Understanding Type 1

These findings are classified as observational—meaning researchers noticed a pattern in the data but haven't yet proven cause and effect. However, they offer a potential new window into how type 1 diabetes may begin. If digestive enzyme function is genuinely involved in type 1 development, it could reshape how scientists think about the disease's origins and eventually how they work to prevent it.

The connection between pancreatic digestive function and autoimmunity is not yet clear, but the consistency of the finding across multiple infants suggests it's worth investigating further.

Not a Test—Yet

It's important to note that these findings are not ready for clinical use. This is not a screening test families can request today to predict type 1 diabetes risk. The research is still in its early stages and represents a research observation, not a validated diagnostic tool.

As always, anyone with concerns about type 1 diabetes risk in their child should speak with their healthcare team about appropriate monitoring and next steps.

Evidence label

Origin: YouTube / T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.